Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification phospholipase A2 receptor (PLA2R) as target antigen in patients changed management MN dramatically, and provided a rationale for B-cell depleting agents such rituximab. efficacy rituximab inducing remission has been investigated several studies, including 3 randomized controlled t...

A 70-year-old male with hypertension, ischemic cardiac diseaseand a chronic kidney disease due to membranous nephropathy, received KT from controlled death donor. He as induction therapy basiliximab.